Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 2, 2011, Pages 84-88

  Panchapakesan, Usha ^a   Pollock, Carol ^a   Saad, Sonia ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diabetic nephropathy; Epidermal growth factor receptor; Kidney; Peroxisome proliferator activated receptor gamma

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALDOSTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM PROTON EXCHANGE PROTEIN 3; TROGLITAZONE;

DIABETIC NEPHROPATHY; DRUG BINDING; GENE EXPRESSION; HOMEOSTASIS; HUMAN; KIDNEY PROXIMAL TUBULE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SODIUM RETENTION; SODIUM TRANSPORT; WATER RETENTION; WATER TRANSPORT;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HOMEOSTASIS; HUMANS; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; PPAR GAMMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SODIUM; SODIUM-HYDROGEN ANTIPORTER; WATER; WATER-ELECTROLYTE BALANCE;

EID: 79151486799     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05472.x     Document Type: Review

References (60)

1. Saad S, Stevens VA, Wassef L et al. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int. 2005; 68: 985-97.
2. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab. Vasc. Dis. Res. 2005; 2: 61-6.
3. Staels B. Fluid retention mediated by renal PPARgamma. Cell Metab. 2005; 2: 77-8.
4. Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol. Dial. Transplant. 2009; 24: 1130-41.
5. Vallon V, Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr. Opin. Nephrol. Hypertens. 2005; 14: 59-66.
6. Nakopoulou L, Stefanaki K, Boletis J et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol. Dial. Transplant. 1994; 9: 764-9.
7. Sis B, Sarioglu S, Celik A, Zeybel M, Soylu A, Bora S. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. Transpl. Immunol. 2004; 13: 229-32.
8. Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J. Biol. Chem. 2003; 278: 35049-56.
9. Andresen BT, Linnoila JJ, Jackson EK, Romero GG. Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells. Hypertension 2003; 41: 781-6.
10. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77: 400-10.
11. Zhuang S, Dang Y, Schnellmann RG. Requirement of the epidermal growth factor receptor in renal epithelial cell proliferation and migration. Am. J. Physiol. Renal Physiol. 2004; 287: F365-72.
12. Nony PA, Schnellmann RG. Mechanisms of renal cell repair and regeneration after acute renal failure. J. Pharmacol. Exp. Ther. 2003; 304: 905-12.
13. Hallman MA, Zhuang S, Schnellmann RG. Regulation of dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor. J. Pharmacol. Exp. Ther. 2008; 325: 520-8.
14. Zhuang S, Schnellmann RG. H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells. Am. J. Physiol. Renal Physiol. 2004; 286: F858-65.
15. Sarro E, Tornavaca O, Plana M, Meseguer A, Itarte E. Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine-induced cell death. Kidney Int. 2008; 73: 77-85.
16. Arany I. Dual role of the activated epidermal growth factor receptor in renal tubular cells during stress. Kidney Int. 2008; 73: 5-7.
17. Gilbert RE, Cox A, McNally PG et al. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 1997; 40: 778-85.
18. Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul. Pharmacol. 2009; 51: 236-45.
19. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J. Vasc. Res. 2005; 42: 284-91.
20. Lautrette A, Li S, Alili R et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 2005; 11: 867-74.
21. Wu D, Peng F, Zhang B et al. EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells. Am. J. Physiol. Renal Physiol. 2009; 297: F822-34.
22. Quigley R, Baum M. Effects of epidermal growth factor and transforming growth factor-alpha on rabbit proximal tubule solute transport. Am. J. Physiol. 1994; 266: F459-65.
23. Geibel J, Giebisch G, Boron WF. Angiotensin II stimulates both Na(+)-H+ exchange and Na+/HCO3- cotransport in the rabbit proximal tubule. Proc. Natl Acad. Sci. USA 1990; 87: 7917-20.
24. Stevens VA, Saad S, Poronnik P, Fenton-Lee CA, Polhill TS, Pollock CA. The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol. Dial. Transplant. 2008; 23: 1834-43.
25. Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int. Suppl. 2007; 106: S27-35.
26. Pearce D, Verrey F, Chen SY et al. Role of SGK in mineralocorticoid-regulated sodium transport. Kidney Int. 2000; 57: 1283-9.
27. Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J. Biol. Chem. 2003; 278: 43060-6.
28. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 2007; 292: E1790-800.
29. Garty H. Regulation of the epithelial Na+ channel by aldosterone: open questions and emerging answers. Kidney Int. 2000; 57: 1270-6.
30. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell. Physiol. Biochem. 2006; 17: 21-8.
31. Krug AW, Papavassiliou F, Hopfer U, Ullrich KJ, Gekle M. Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders. Pflugers Arch. 2003; 446: 492-6.
32. Ohga S, Shikata K, Yozai K et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal Physiol. 2007; 292: F1141-50.
33. Goyal A, Crook ED. Thiazolidinediones and progression of renal disease in patients with diabetes. J. Investig. Med. 2006; 54: 56-61.
34. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am. J. Kidney Dis. 2010; 55: 835-47.
35. Buckingham RE, Al-Barazanji KA, Toseland CD et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-34.
36. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-32.
37. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int. 2000; 58: 2341-50.
38. Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am. J. Physiol. Renal Physiol. 2004; 287: F528-34.
39. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J. Am. Soc. Nephrol. 2005; 16: 638-45.
40. Panchapakesan U, Sumual S, Pollock CA, Chen X. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am. J. Physiol. Renal Physiol. 2005; 289: F1153-8.
41. Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy - relevance to renoprotection. Nat. Clin. Pract. Nephrol. 2005; 1: 33-43.
42. Zafiriou S, Stanners SR, Polhill TS, Poronnik P, Pollock CA. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 2004; 65: 1647-53.
43. Ishibashi K, Kuwahara M, Gu Y et al. Cloning and functional expression of a new water channel abundantly expressed in the testis permeable to water, glycerol, and urea. J. Biol. Chem. 1997; 272: 20782-6.
44. Sabolic I, Valenti G, Verbavatz JM et al. Localization of the CHIP28 water channel in rat kidney. Am. J. Physiol. 1992; 263: C1225-33.
45. Sohara E, Rai T, Miyazaki J, Verkman AS, Sasaki S, Uchida S. Defective water and glycerol transport in the proximal tubules of AQP7 knockout mice. Am. J. Physiol. Renal Physiol. 2005; 289: F1195-200.
46. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J. Pharmacol. Exp. Ther. 2004; 308: 426-33.
47. Kishida K, Shimomura I, Nishizawa H et al. Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2001; 276: 48572-9.
48. Rozansky DJ, Wang J, Doan N et al. Hypotonic induction of SGK1 and Na+ transport in A6 cells. Am. J. Physiol. Renal Physiol. 2002; 283: F105-13.
49. Muto S, Miyata Y, Imai M, Asano Y. Troglitazone stimulates basolateral rheogenic Na+/HCO3- cotransport activity in rabbit proximal straight tubules. Exp. Nephrol. 2001; 9: 191-7.
50. Panchapakesan U, Pollock C, Saad S. Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology (Carlton) 2009; 14: 298-301.
51. Tencer L, Burgermeister E, Ebert MP, Liscovitch M. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Anticancer Res. 2008; 28: 895-906.
52. Slomiany BL, Slomiany A. Role of epidermal growth factor receptor transactivation in PPAR gamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis. Inflammopharmacol 2004; 12: 177-88.
53. Slomiany BL, Slomiany A. Src kinase-dependent epidermal growth factor receptor transactivation in PPARgamma ligand-induced suppression of Porphyromonas gingivalis interference with salivary mucin synthesis. IUBMB Life 2004; 56: 153-9.
54. Li X, Yang X, Xu Y et al. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. Cell Res. 2009; 19: 720-32.
55. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J. Biol. Chem. 2003; 278: 46261-9.
56. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-54.
57. Dewar BJ, Gardner OS, Chen CS, Earp HS, Samet JM, Graves LM. Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones. Mol. Pharmacol. 2007; 72: 1146-56.
58. Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol. Pharmacol. 2005; 68: 933-41.
59. Fretz MM, Dolman ME, Lacombe M et al. Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. J. Control. Release 2008; 132: 200-7.
60. Beltowski J, Lowicka E. EGF receptor as a drug target in arterial hypertension. Mini Rev. Med. Chem. 2009; 9: 526-38.